Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...
Early, Sustained and Statistically Significant Reduction in Plasma P-tau 181 Reaching 31% at 24 Months Observed in Carriers of One or Two Copies of APOE4 Gene, who Represent Two Thirds of Alzheimer’s ...
Researchers have uncovered a pattern of Alzheimer disease (AD) biomarker activity that differs from the accepted trajectory and could affect future clinical trials. Led by Anne M. Fagan, PhD, research ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of exploratory analyses on cerebrospinal fluid (CSF) ...
With amyloid immunotherapy in clinical use, scientists need to find better ways to identify the patients most at risk of developing ARIA (see part 16 of this series). One of the biggest danger signs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results